In previous studies performed in SMA mouse models treated with therapeutically beneficial doses of DAQ-DcpSi, SMN full length transcripts have been reported to either increase modestly [7], or not to change [8, 9]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.